1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued

TRAXV
First Tracks Biotherapeutics, Inc. Ordinary Shares When-IssuedUS flagNASDAQ Global Select
22.51
USD
+3.51
- -
782.20MMarket Cap

Income Statement (USD)

APIChatGPT
2023 Y
2024 Y
As of date
12/31/2023
12/31/2024
Sales/Revenue/Turnover
- -
- -
+ Sales & Services Revenue
- -
- -
- Cost of Revenue
- -
- -
+ Cost of Goods & Services
- -
- -
Gross Profit
- -
- -
+ Other Operating Income
- -
- -
- Operating Expenses
118
181
+ Selling, General & Admin
21
29
+ Research & Development
98
152
+ Other Operating Expense
- -
- -
Operating Income (Loss)
-118
-181
- Non-Operating (Income) Loss
-12
-17
+ Interest Expense, Net
-12
-17
+ Interest Expense
- -
- -
- Interest Income
12
17
+ Other Non-Op (Income) Loss
- -
- -
Pretax Income
-106
-164
- Income Tax Expense (Benefit)
- -
- -
- (Income) Loss from Affiliates
- -
- -
Income (Loss) from Cont Ops
-106
-164
- Net Extraordinary Losses (Gains)
- -
- -
+ Discontinued Operations
- -
- -
+ Extraord. & Accounting Changes
- -
- -
Income (Loss) Incl. MI
-106
-164
- Minority Interest
- -
- -
Net Income, GAAP
-106
-164
- Preferred Dividends
- -
- -
- Other Adjustments
- -
- -
Net Income Avail to Common, GAAP
-106
-164
EBIT
-118
-181
EBITDA
-116
-179
EBITDA Margin (%)
- -
- -
EBITA
-118
-181
Gross Margin (%)
- -
- -
Operating Margin (%)
- -
- -
Profit Margin (%)
- -
- -
Sales per Employee
- -
- -
Dividend per Share
- -
- -
Depreciation Expense
2
2
Basic Weighted Avg Shares
35
- -
Basic EPS, GAAP
-3.05
- -
Basic EPS from Cont Ops
-3.05
- -
Diluted Weighted Avg Shares
35
- -
Diluted EPS, GAAP
-3.05
- -
Diluted EPS from Cont Ops
-3.05
- -

Balance Sheet (USD)

APIChatGPT
2023 Y
2024 Y
As of date
12/31/2023
12/31/2024
Total Current Assets
399
390
+ Cash, Cash Equivalents & STI
391
385
+ Cash & Cash Equivalents
36
123
+ ST Investments
355
262
+ Accounts & Notes Receiv
- -
- -
+ Accounts Receivable, Net
- -
- -
+ Notes Receivable, Net
- -
- -
+ Loans Receivable, Net
- -
- -
+ Other Receivable, Net
- -
- -
+ Inventories
- -
- -
+ Raw Materials
- -
- -
+ Work In Process
- -
- -
+ Finished Goods
- -
- -
+ Inventory Adjustments
- -
- -
+ Other Inventory
- -
- -
+ Other ST Assets
8
5
+ Misc ST Assets
- -
- -
+ Prepaid Expenses
- -
- -
+ ST Derivative & Hedging Assets
- -
- -
+ ST Assets Held-for-Sale
- -
- -
+ ST Deferred Tax Assets
- -
- -
Total Noncurrent Assets
46
52
+ Property, Plant & Equip, Net
18
16
+ Property, Plant & Equip
24
23
- Accumulated Depreciation
6
7
+ LT Investments & Receivables
27
35
+ LT Investments
27
35
+ LT Receivables
- -
- -
+ Other LT Assets
- -
- -
+ Total Intangible Assets
- -
- -
+ Goodwill
- -
- -
+ Other Intangible Assets
- -
- -
+ LT Deferred Tax Assets
- -
- -
+ LT Derivative & Hedging Assets
- -
- -
+ Misc LT Assets
- -
- -
Total Assets
444
442
+ Payables & Accruals
12
27
+ Accounts Payable
2
4
+ Accrued Taxes
- -
- -
+ Interest & Dividends Payable
- -
- -
+ Other Payables & Accruals
9
23
+ ST Debt
2
2
+ ST Borrowings
- -
- -
+ ST Finance Leases
2
2
+ Other ST Liabilities
5
7
+ Deferred Revenue
- -
- -
+ Derivatives & Hedging
- -
- -
+ Deferred Tax Liabilities
- -
- -
+ Misc ST Liabilities
5
7
Total Current Liabilities
18
36
+ LT Debt
16
14
+ LT Borrowings
- -
- -
+ LT Finance Leases
16
14
+ Other LT Liabilities
- -
- -
+ Accrued Liabilities
- -
- -
+ Pension Liabilities
- -
- -
+ Deferred Revenue
- -
- -
+ Deferred Tax Liabilities
- -
- -
+ Derivatives & Hedging
- -
- -
+ Misc LT Liabilities
- -
- -
Total Noncurrent Liabilities
16
14
Total Liabilities
34
50
+ Preferred Equity and Hybrid Capital
- -
- -
+ Share Capital & APIC
411
391
+ Common Stock
411
391
+ Additional Paid in Capital
- -
- -
- Treasury Stock
- -
- -
+ Retained Earnings
- -
- -
+ Other Equity
-1
- -
Equity Before Minority Interest
410
392
+ Minority/Non Controlling Interest
- -
- -
Total Equity
410
392
Total Liabilities & Equity
444
442
Shares Outstanding
35
35
Number of Employees
- -
- -
Capital Leases - Total
18
16
Net Debt
-36
-123
Net Debt to Equity
-8.78
-31.43
Tangible Common Equity Ratio
92.29
88.62
Current Ratio
21.87
10.78
Cash Conversion Cycle
- -
- -

Cash Flow Statement (USD)

APIChatGPT
2023 Y
2024 Y
As of date
12/31/2023
12/31/2024
+ Net Income
-106
-164
+ Depreciation & Amortization
2
2
+ Non-Cash Items
8
17
+ Stock-Based Compensation
18
27
+ Deferred Income Taxes
- -
- -
+ Asset Impairment Charge
- -
- -
+ Other Non-Cash Adj
-11
-10
+ Chg in Non-Cash Work Cap
3
19
+ (Inc) Dec in Accts Receiv
- -
- -
+ (Inc) Dec in Inventories
- -
- -
+ (Inc) Dec in Prepaid Assets
-4
3
+ Inc (Dec) in Accts Payable
8
18
+ Inc (Dec) in Other
-2
-2
+ Net Cash From Disc Ops
- -
- -
Cash from Operating Activities
-93
-126
+ Change in Fixed & Intang
- -
- -
+ Disp in Fixed & Intang
- -
- -
+ Disp of Fixed Prod Assets
- -
- -
+ Disp of Intangible Assets
- -
- -
+ Acq of Fixed & Intang
-1
- -
+ Acq of Fixed Prod Assets
-1
- -
+ Acq of Intangible Assets
- -
- -
+ Cash (Repurchase) of Equity
- -
- -
+ Increase in Capital Stock
- -
- -
+ Decrease in Capital Stock
- -
- -
+ Net Change in LT Investment
146
96
+ Dec in LT Investment
449
476
+ Inc in LT Investment
-304
-380
+ Net Cash From Acq & Div
- -
- -
+ Cash from Divestitures
- -
- -
+ Cash for Acq of Subs
- -
- -
+ Cash for JVs
- -
- -
+ Other Investing Activities
- -
- -
+ Net Cash From Disc Ops
- -
- -
Cash from Investing Activities
145
95
+ Dividends Paid
- -
- -
+ Net Cash From Debt
- -
- -
+ Cash From Debt
- -
- -
+ Repayments of Debt
- -
- -
+ Other Financing Activities
-87
118
+ Net Cash From Disc Ops
- -
- -
Cash from Financing Activities
-87
118
Effect of Foreign Exchange Rates
- -
- -
Net Changes in Cash
-35
87
EBITDA
-116
-179
EBITDA Margin (%)
- -
- -
Free Cash Flow
-94
-126
Net Cash Paid for Acquisitions
- -
- -
Free Cash Flow to Firm
- -
- -
Free Cash Flow to Equity
- -
-126
Free Cash Flow per Basic Share
-2.7
- -
Price/Free Cash Flow
- -
- -
Cash Flow to Net Income
0.88
0.77
Capital Expenditures
-1
- -